WuXi PharmaTech said that Laboratory Testing Division (LTD) has launched preclinical medical device testing servicesin China. These services are being offered for Chinese and international clients for their product registration with the China Food and Drug Administration (CFDA) and for Chinese clients for product registration in global markets.
WuXi's operations in Shanghai and Suzhou have successfully passed inspections by the FDA, CFDA, and OECD and audits by many clients for GLP studies. The company has the world-class laboratory and AAALAC-inspected animal facility headed by a highly experienced international management team and staffed by well-trained technicians.
"China's medical device industry is growing rapidly, and WuXi is committed to providing domestic and international medical device companies with the same high quality of testing services in China that we have provided for years in the United States," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This new service offering brings WuXi one step closer to achieving our vision of offering a complete platform of R&D services for global life-science companies."